Ancon technologies manufacture equipment and components to detect trace elements in the air, things such as explosives, drugs and chemical weapons. The technology created by Ancon is around 10,000x more sensitive than anything on the market at the moment.
days to go:
Expired
investment:
£457,000
Arcade is an innovative provider of technology (patent pendinG) that empowers telecom carriers to offer life-changing gigabit broadband over existing networks, with rapid deployment and ROI in under a year. Their solutions enable gigabit speeds everywhere, complementing fiber strategies and avoiding extensive cable replacements.
days to go:
Expired
investment:
£350,000
Aveqia is a unique interactive gastronomic experience combining a luxury restaurant with state of the art kitchens to create an exceptional venue for corporate events or private groups. These experiences are run by Michelin star trained chefs.
days to go:
Expired
investment:
£100,000
Aveqia London is a unique interactive gastronomic experience combining a luxury restaurant with state of the art kitchens to create an exceptional venue for corporate events or private groups. Aveqia gives clients or colleagues the opportunity to work together to prepare and consume cuisine.
days to go:
Expired
investment:
£100,000
Billon have created a technology that enables zero cost global payments by the use of a simple mobile app. Billon's mobile app allows you to instantly pay for the rest of an article from the Guardian or even donate to your favourite Youtubers with a few clicks of a button.
days to go:
Expired
investment:
£1,406,667
Bodytrak is a wearable technology that monitors physiological activity such as heart rate and core body temperature. This real time data is analysed using cloud based technology and algorithms to supervisors or commanders so early action can be taken on the event of illness or injury.
days to go:
Expired
investment:
£1,123,119
Brands reunited are looking to disrupt the modern craft beer market. Their sales are over £400k and are growing 100% year on year. They have two brands that are already in Watneys and Home Ales. The funding will be spent on building their brand and the team.
days to go:
Expired
investment:
£255,000
Cable Software Limited (“Cable Software” or the “Company”) aspires to become the recognised B2B cloud based procurement exchange across the high-end regulated medi-markets. Initially, the Company is focusing upon the dental market before moving into veterinary, ophthalmic and general medicine. Helping dentists to work closely together.
days to go:
Expired
investment:
£10,000
Care Line Live is an award-winning revolutionary monitoring and management platform for Home Care Agencies. CLL is a client-based system that enables home care agencies to run their businesses from any place. It reduces administration, automates processes, easily rosters client visits and improves efficiency and productivity by giving the client more Time to Care. It increases client and carer satisfaction, provides accessible and responsive support, increases compliance for CQC purposes, generates higher profits through improved efficiency and capacity. The future product road map includes integration with 3rd party home automation platforms that will allow home care agencies to offer further services to their clients, such as secure key-less entry.
days to go:
Expired
investment:
£367,000
Ceryx Medical is a medical technological entity that is developing bioelectronics based on a unique, patent-protected, chip technology that can mimic nerve centres within the body called Central Pattern Generators (CPGs). CPGs help to control a range of autonomic or rhythmical processes within the body such as peristalsis, heart rate, and even walking. The Ceryx system resembles a traditional cardiac pacing device that holds a lot of promise in potentially alleviating incidences of heart failure leading to a therapeutic effect on patient health. In the UK, this is a day surgery procedure under local anaesthetic with a basic system costing around £3500. The device, therefore, offers a cost-effective, single procedure solution for this currently intractable disease. Treatment expenditures on heart failure cases in the EU amount to almost £35 billion. The Ceryx system is a potential disruptor in this segment and offers multiple potential applications. The company is targeting £500,000 as part of £1 million round. With the investment, the company aims to produce a data package that mimics those used to support 510k/NDA applications, as mandated by the US Food and Drug Administration (FDA), for current devices and drugs used to treat heart failure.
days to go:
Expired
investment:
Withheld
